EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Low Specific T‐Cell Immunity Against Mpox Elicited in People With HIV‐1 and PrEP Users After Subcutaneous Vaccination Compared to Natural Infection

Olivia de la Calle-Jiménez iD, Guiomar Casado-Fernández, Inés Armenteros-Yeguas, Luis Lemus-Aguilar, Begoña Baza, Jorge Alfredo Pérez-García, Javier Rodríguez-Añover, Elena Mateos, Reynaldo Homen, Eva Orviz-García iD, Noemí Cabello, Anabel Negredo und 5 weitere

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Olivia de la Calle-Jiménez und 16 weiteren Autor:innen. Beteiligte Einrichtung: Immunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Infections, Immunity, Cellular, Mpox, Monkeypox. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This work was supported by NIH grant R01AI143567; the Spanish Ministry of Science and Innovation, grant PID2022-141317OB-I00 funded by MICIU/AEI /10.13039/5011…, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In August 2024, the World Health Organization declared mpox infection a Public Health Emergency of International Concern for second time since 2022 and recommended vaccinating all people at‐risk, such as people with HIV‐1 (PWH) and prophylaxis pre‐exposition (PrEP) users. We recruited PWH and PrEP users who received one or two doses of subcutaneous Imvanex® or Jynneos® and compared specific T‐cell immunity with participants who passed mpox natural infection or were Nonexposed to mpox. CD4 + T cells from people who had mpox showed the highest capacity to produce IL‐2 (1.8‐fold, p = 0.0328), as well as IFNγ (2.5‐fold, p = 0.0247), and IL‐4 (1.8‐fold, p = 0.0373) from naïve CD4 + T cells, in response to MHC‐II‐restricted mpox‐related peptides, compared to vaccinated participants. CD8 + T cells from individuals who had mpox also showed the highest capacity to produce IFN (1.6‐fold, p = 0.0321) and TNF (2.1‐fold, p = 0.0084) against MHC‐I‐restricted peptides. Therefore, the most potent and robust T‐cell responses were developed after mpox infection, while they were barely detectable after vaccination. These results support the need to explore booster doses or improved vaccines to enhance cellular immunity in at‐risk populations. More studies are needed to evaluate the capacity of mpox vaccines to confer long‐term protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS VaccinesHIV InfectionsImmunity, CellularMpox, MonkeypoxAdultFemaleHumansMaleMiddle AgedYoung AdultCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHIV-1Injections, SubcutaneousInterferon-gammaInterleukin-2Pre-Exposure ProphylaxisVaccination

Stichwörter der Autor:innen

CD4 + T cellsCD8 + T cellsHIV‐1MPXVPrEPmpox

Substanzen

AIDS VaccinesInterferon-gammaInterleukin-2

Autor:innen und Institutionen

  • Immunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
  • Infectious Diseases Unit, Internal Medicine Service, Hospital Clínico San Carlos-IdISSC, Madrid, Spain.
  • Biomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
  • Faculty of Sciences, Universidad de Alcalá, Madrid, Spain.
  • Centro Sanitario Sandoval, Hospital Clínico San Carlos-IdISSC, Madrid, Spain.
  • Universidad Complutense de Madrid, Madrid, Spain.

ORCID-Profile: Olivia de la Calle-Jiménez, Eva Orviz-García, María Paz Sánchez Seco, Mayte Coiras

Förderung

  • This work was supported by NIH grant R01AI143567; the Spanish Ministry of Science and Innovation, grant PID2022-141317OB-I00 funded by MICIU/AEI /10.13039/5011…
  • NIAID NIH HHS

Zitieren

APA

Calle-Jiménez, O., Casado-Fernández, G., Armenteros-Yeguas, I., Lemus-Aguilar, L., Baza, B., Pérez-García, J. A., Rodríguez-Añover, J., Mateos, E., Homen, R., Orviz-García, E., Cabello, N., Negredo, A., Seco, M. P. S., Del Romero, J., Estrada, V., Torres, M., & Coiras, M. (2025). Low Specific T‐Cell Immunity Against Mpox Elicited in People With HIV‐1 and PrEP Users After Subcutaneous Vaccination Compared to Natural Infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.70498

Vancouver

Calle-Jiménez O, Casado-Fernández G, Armenteros-Yeguas I, Lemus-Aguilar L, Baza B, Pérez-García JA, et al. Low Specific T‐Cell Immunity Against Mpox Elicited in People With HIV‐1 and PrEP Users After Subcutaneous Vaccination Compared to Natural Infection. Journal of Medical Virology. 2025. doi:10.1002/jmv.70498

BibTeX
@article{CalleJimnez2025,
  author = {Calle-Jiménez, Olivia de la and Casado-Fernández, Guiomar and Armenteros-Yeguas, Inés and Lemus-Aguilar, Luis and Baza, Begoña and Pérez-García, Jorge Alfredo and Rodríguez-Añover, Javier and Mateos, Elena and Homen, Reynaldo and Orviz-García, Eva and Cabello, Noemí and Negredo, Anabel and Seco, María Paz Sánchez and Del Romero, Jorge and Estrada, Vicente and Torres, Montserrat and Coiras, Mayte},
  title = {Low Specific T‐Cell Immunity Against Mpox Elicited in People With HIV‐1 and PrEP Users After Subcutaneous Vaccination Compared to Natural Infection},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70498}
}
Kostenlos starten →